KR20100053541A - 프로스타글란딘 e1을 포함하는 안정한 지방 유제 - Google Patents
프로스타글란딘 e1을 포함하는 안정한 지방 유제 Download PDFInfo
- Publication number
- KR20100053541A KR20100053541A KR1020107002368A KR20107002368A KR20100053541A KR 20100053541 A KR20100053541 A KR 20100053541A KR 1020107002368 A KR1020107002368 A KR 1020107002368A KR 20107002368 A KR20107002368 A KR 20107002368A KR 20100053541 A KR20100053541 A KR 20100053541A
- Authority
- KR
- South Korea
- Prior art keywords
- fat emulsion
- prostaglandin
- activity
- compound
- fat
- Prior art date
Links
- 239000002960 lipid emulsion Substances 0.000 title claims abstract description 79
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title claims description 34
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title description 2
- 229960000711 alprostadil Drugs 0.000 title description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title 1
- 239000011521 glass Substances 0.000 claims abstract description 46
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 238000003860 storage Methods 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims description 38
- 239000003708 ampul Substances 0.000 claims description 35
- 230000001954 sterilising effect Effects 0.000 claims description 29
- 238000004659 sterilization and disinfection Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000000839 emulsion Substances 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229910052814 silicon oxide Inorganic materials 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 description 13
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 12
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000012086 standard solution Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2007-184358 | 2007-07-13 | ||
JP2007184358 | 2007-07-13 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020157002118A Division KR101588558B1 (ko) | 2007-07-13 | 2008-07-11 | 프로스타글란딘 e1을 포함하는 안정한 지방 유제 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20100053541A true KR20100053541A (ko) | 2010-05-20 |
Family
ID=40259458
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107002368A KR20100053541A (ko) | 2007-07-13 | 2008-07-11 | 프로스타글란딘 e1을 포함하는 안정한 지방 유제 |
KR1020157002118A KR101588558B1 (ko) | 2007-07-13 | 2008-07-11 | 프로스타글란딘 e1을 포함하는 안정한 지방 유제 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020157002118A KR101588558B1 (ko) | 2007-07-13 | 2008-07-11 | 프로스타글란딘 e1을 포함하는 안정한 지방 유제 |
Country Status (6)
Country | Link |
---|---|
JP (2) | JP5890599B2 (fr) |
KR (2) | KR20100053541A (fr) |
CN (1) | CN101743010A (fr) |
MY (1) | MY158088A (fr) |
TW (1) | TW200920379A (fr) |
WO (1) | WO2009011112A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102038639B (zh) * | 2010-12-24 | 2012-05-02 | 海南碧凯药业有限公司 | 一种前列地尔注射制剂 |
CN102198095A (zh) * | 2011-05-03 | 2011-09-28 | 北京中海康医药科技发展有限公司 | 一种依前列醇脂肪乳及其制备方法 |
JP5759804B2 (ja) * | 2011-06-27 | 2015-08-05 | 富士フイルム株式会社 | 容器詰製剤 |
CN107519132A (zh) * | 2017-08-29 | 2017-12-29 | 辅必成(上海)医药科技有限公司 | 一种前列地尔的纳米脂肪乳剂 |
WO2019230964A1 (fr) * | 2018-05-31 | 2019-12-05 | 富士フイルム株式会社 | Composition d'émulsion de type huile dans eau conditionnée |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2815595B2 (ja) * | 1988-12-27 | 1998-10-27 | 松本製薬工業株式会社 | 医療用ガラス製品内表面の金属酸化物処理によるアルカリ等の溶出防止法 |
JP3268470B2 (ja) * | 1992-11-18 | 2002-03-25 | 興亜硝子株式会社 | 溶出防止機能を有するガラス製品の製造方法 |
JPH0769897A (ja) * | 1993-09-01 | 1995-03-14 | Green Cross Corp:The | 血中トリグリセリド低下作用剤 |
JPH07206472A (ja) * | 1994-01-12 | 1995-08-08 | Nippon Electric Glass Co Ltd | 医薬用ホウケイ酸ガラス |
JPH08104620A (ja) * | 1994-10-05 | 1996-04-23 | Green Cross Corp:The | 薬物含有脂肪乳剤 |
JPH08175998A (ja) * | 1994-12-19 | 1996-07-09 | Takada Seiyaku Kk | シリコート容器を用いた凍結乾燥製剤 |
JPH09235230A (ja) * | 1995-12-29 | 1997-09-09 | Hisamitsu Pharmaceut Co Inc | イオントフォレーシス用製剤 |
CA2302023A1 (fr) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries Ltd. | Promoteurs de neovascularisation |
JP2001328612A (ja) * | 2000-05-22 | 2001-11-27 | Daiwa Tokushu Glass Kk | 低アルカリガラス容器及びその製造方法 |
JP2006188474A (ja) * | 2005-01-07 | 2006-07-20 | Nichi-Iko Pharmaceutical Co Ltd | 安定性に優れた脂肪乳剤 |
-
2008
- 2008-07-11 WO PCT/JP2008/001865 patent/WO2009011112A1/fr active Application Filing
- 2008-07-11 CN CN200880024114A patent/CN101743010A/zh active Pending
- 2008-07-11 MY MYPI20095677A patent/MY158088A/en unknown
- 2008-07-11 KR KR1020107002368A patent/KR20100053541A/ko active Application Filing
- 2008-07-11 TW TW097126460A patent/TW200920379A/zh unknown
- 2008-07-11 JP JP2009523535A patent/JP5890599B2/ja active Active
- 2008-07-11 KR KR1020157002118A patent/KR101588558B1/ko active IP Right Grant
-
2014
- 2014-07-18 JP JP2014147416A patent/JP5965944B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20150017775A (ko) | 2015-02-17 |
JP5890599B2 (ja) | 2016-03-22 |
JP2014224131A (ja) | 2014-12-04 |
JP5965944B2 (ja) | 2016-08-10 |
CN101743010A (zh) | 2010-06-16 |
TW200920379A (en) | 2009-05-16 |
MY158088A (en) | 2016-08-30 |
JPWO2009011112A1 (ja) | 2010-09-16 |
WO2009011112A1 (fr) | 2009-01-22 |
KR101588558B1 (ko) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3248599B1 (fr) | Composition auto-émulsifiante d'acides gras omega-3 | |
AU2019200649B2 (en) | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid | |
RU2678433C2 (ru) | Депо-составы гидрофобного активного ингредиента и способы их получения | |
KR20080092373A (ko) | 치료용 조성물 | |
JP2015521182A (ja) | 薬物のための眼科用ビヒクルシステム、眼科用キットおよび眼科用組成物の使用 | |
JP5965944B2 (ja) | プロスタグランジンe1を含む安定な脂肪乳剤 | |
JP6976594B2 (ja) | ソフト抗コリン類似体のための製剤 | |
JP5345744B1 (ja) | 網膜疾患の予防、改善、又は治療剤 | |
KR20150041794A (ko) | 오피오이드 제형 | |
Macoon et al. | In vitro release of hydrophobic drugs by oleogel rods with biocompatible gelators | |
JP5021887B2 (ja) | アゼチジン誘導体に基づく医薬組成物 | |
CN102202509A (zh) | 用于治疗牛皮癣的稳定化组合物 | |
JPWO2020059543A1 (ja) | 生体材料 | |
CA3018670A1 (fr) | Gel viscoelastique de liraglutide concu pour une administration une fois par semaine ou une fois toutes les deux semaines | |
CN109715138A (zh) | 前列环素类似物制剂 | |
KR20190110563A (ko) | 지방 유제, 및 그 제조 방법, 지방 유제의 안정성을 향상시키는 방법, 그리고 지방 유제의 안정성 향상제 | |
WO2016038626A1 (fr) | Compositions pharmaceutiques de vitamine kl | |
CA2815477A1 (fr) | Composition pharmaceutique destinee a une application topique renfermant un phospholipide | |
Wang et al. | Ionic liquid pilocarpine analog as an antiglaucoma drug candidate | |
Franzè et al. | Micelles-in-liposome systems obtained by proliposomal approach for cannabidiol delivery: structural features and skin penetration | |
JP2013520435A (ja) | タキサンのプロエマルジョン製剤ならびにその製造方法および使用 | |
JPH04300833A (ja) | プロスタグランジンe1 含有脂肪乳剤充填噴霧剤 | |
US20130309215A1 (en) | Pharmaceutical composition | |
US20210038503A1 (en) | Compositions and methods for topical treatment of dermal and ocular conditions | |
KR20170137117A (ko) | 피부용의 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
A107 | Divisional application of patent | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150126 Effective date: 20160628 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2016201006432; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160826 Effective date: 20170817 |